InventisBio's D-2570 Demonstrates Efficacy in Treating Severe Psoriasis in Phase 2 Study

Promising Phase 2 Results for D-2570 in Psoriasis Treatment

Overview of Findings

InventisBio Co., Ltd. has reported encouraging outcomes from their Phase 2 clinical trial involving D-2570, a novel oral selective inhibitor targeting TYK2 kinase, designed specifically for patients suffering from moderate to severe plaque psoriasis. The results demonstrate not only remarkable efficacy in achieving significant skin clearance but also maintain a solid safety profile, forming a basis for potential advancements in treatment options for psoriasis patients.

Study Design

The study was a robust multicenter, double-blind, placebo-controlled trial that examined the effects of D-2570 on participants with varying degrees of plaque psoriasis severity. A total of 161 patients were enrolled and randomized into three different dosing groups, receiving D-2570 or a placebo. Key results were observed regarding the Psoriasis Area and Severity Index (PASI) – a widely recognized scale used to measure the severity and coverage of psoriasis.

Efficacy Outcomes

The trial's primary endpoint, a reduction of 75% or more in the PASI score (referred to as PASI 75), was remarkably achieved by over 85% of patients in all dosing groups of D-2570 within just 12 weeks, starkly contrasting with the 12.5% noted in the placebo group. More impressively, half of those patients receiving the higher dose achieved full skin clearance (PASI 100), compared to only 2.5% from the placebo group.

Further analysis reveals that even secondary endpoints showcased positive outcomes for D-2570: 77.5% of patients in the high-dose group met PASI 90 (90% improvement), and 87.5% achieved scores indicating low disease activity as assessed by static Physician's Global Assessment (sPGA).

Safety Assessment

In terms of safety, D-2570 was shown to be well-tolerated among participants, with no serious adverse events reported throughout the study. The minor adverse effects recorded were predominantly mild to moderate (CTCAE Grade 1 or 2), which aligns with safety patterns observed in other TYK2 inhibitors currently in clinical trials or with market approval. No novel safety issues were identified, cementing the profile of D-2570 as both effective and safe for further clinical exploration.

Clinical Implications

The advances demonstrated with D-2570 are particularly noteworthy, as moderate to severe plaque psoriasis significantly impacts patients' well-being and overall quality of life. Dr. Ling Zhang, Chief Medical Officer at InventisBio, emphasized the substantial potential for D-2570 in delivering efficacy similar to leading biologics and IL-23 targeted therapies while providing the convenience of an oral formulation.

Future Directions

Looking ahead, InventisBio has committed to further pushing the development of D-2570, aiming to broaden treatment avenues for individuals enduring autoimmune conditions such as psoriasis as well as inflammatory bowel diseases. Complete data from this trial is set to be presented at forthcoming scientific conferences, where the broader medical community can explore its findings.

About D-2570 and InventisBio

D-2570 functions as an oral TYK2 JH2 pseudokinase domain inhibitor, primarily focused on controlling cytokine signaling pathways integral to autoimmune responses. InventisBio, a clinical-stage biotechnology enterprise, is unwavering in its mission to create and offer innovative small-molecule therapies aimed at cancers, metabolic disorders, and autoimmune diseases. Leveraging its strong research pipeline, the company prioritizes addressing unmet medical needs, aspiring to transform patient care globally.